Expertise in
24
conditions

Dr. Ryan T. Merrell

Neurology
Vanderbilt Neurosurgery
1500 21st Ave S Ste 1506, 
Nashville, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
24
conditions
Vanderbilt Neurosurgery
1500 21st Ave S Ste 1506, 
Nashville, TN 

Overview

Ryan Merrell is a Neurologist practicing medicine in Nashville, Tennessee.

Dr. Merrell is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Glioma, Astrocytoma, Gliomatosis Cerebri, and Hormone Replacement Therapy (HRT).

He is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 9 clinical trials. Dr. Merrell is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in IL

Hospital Affiliations

Cookeville Regional Medical Center
Swedish Hospital
Northshore University Healthsystem - Evanston Hospital
Vanderbilt Wilson County Hospital
Vanderbilt University Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Vanderbilt Neurosurgery
1500 21st Ave S Ste 1506, Nashville, TN 37212

Additional Areas of Focus

Dr. Merrell has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: June 25, 2026
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: April 22, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

44 Total Publications

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2026
Similar Doctors
Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Vanderbilt University Transplant Center

1161 21st Ave S, 
Nashville, TN 
 (0.7 miles away)
615-936-0060
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Claassen is a Neurologist practicing medicine in Nashville, Tennessee. Dr. Claassen is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Huntington Disease, Chorea, Movement Disorders, Drug Induced Dyskinesia, and Deep Brain Stimulation. Dr. Claassen is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Vanderbilt Neurology

2220 Pierce Ave Ste B1053, 
Nashville, TN 
 (0.5 miles away)
615-322-5000
Languages Spoken:
English, Arabic, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Bassel Abou-Khalil is a Neurologist practicing medicine in Nashville, Tennessee. Dr. Abou-Khalil is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Seizures, Epilepsy, Photosensitive Epilepsy, and Generalized Tonic-Clonic Seizure. Dr. Abou-Khalil is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Vanderbilt Neurology The Vanderbilt Clinic

1301 Medical Center Dr Ste 3930, 
Nashville, TN 
 (2.4 miles away)
615-322-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Isaacs is a Neurologist practicing medicine in Nashville, Tennessee. Dr. Isaacs is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Tourette Syndrome, Movement Disorders, Drug Induced Dyskinesia, Transient Tic Disorder, and Deep Brain Stimulation. Dr. Isaacs is currently accepting new patients.

Frequently Asked Questions about Dr. Ryan T. Merrell

How do I make an appointment with Dr. Ryan T. Merrell?

You can book an appointment with Dr. Ryan T. Merrell by calling their office at 615-322-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ryan T. Merrell a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ryan T. Merrell is classified as an Elite expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ryan T. Merrell specialize in?

While Dr. Ryan T. Merrell is a Neurology, they have specific expertise in Glioblastoma, Glioma, and Astrocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Ryan T. Merrell participate in research or clinical trials?

Yes. Dr. Ryan T. Merrell has published 44 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. Ryan T. Merrell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ryan T. Merrell accept my insurance?

Dr. Ryan T. Merrell accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 615-322-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Merrell's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile